AKRO News and Press, Akero Therapeutics Inc. From 05/13/20

Akero Therapeutics (NASDAQ: AKRO ): Q1 GAAP EPS of -$0.42 beats by $0.19 . More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., May 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NAS...

In our previous assessment, we compared 13 NASH drug candidates, and our favorite was AK-001 of Akero Therapeutics (AKRO). We emphasized the high likelihood of Akero Therapeutics to reach the best results in NASH treatment among the 2nd wave NASH drug candidates. For those who are interested, ...

SG Blocks (NASDAQ: SGBX ) +100%  on Q4 results .. More news on: SG Blocks, Inc., EyeGate Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Stocks on the move, , Read more ...

Akero Therapeutics (NASDAQ: AKRO ) announces  positive results from a Phase 2 clinical trial, BALANCED , evaluating lead candidate AKR-001 patients with F1-F4 (minimal fibrosis to severe fibrosis) nonalcoholic steatohepatitis (NASH). More news on: Akero Therapeutics, Inc., Healthcar...

SAN FRANCISCO , March 31, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that all three AKR-001 dose groups in the BALANCED study met the primary endpoint of absolute change from baseline in liver fat as measured by magnetic resonance imaging – proton ...

SAN FRANCISCO , March 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss the primary endpoint and other Week 12 efficacy endpoint results from the ongoing Phase 2a BALANCED study of AKR-001 in patients with biopsy-confir...

Akero Therapeutics (NASDAQ: AKRO ): Q4 GAAP EPS of -$0.55 beats by $0.06 . More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO , March 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) Company developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients, to...

In my previous article regarding NASH disease and the potential winners of the first wave drugs, I made a comparison of efficacy of the late stage drug candidates which have better chances to be first in the market of NASH. For those who are interested, please click here . In this article, ...